Danggui Buxue Decoction enhances the anticancer activity of gemcitabine and alleviates gemcitabine-induced myelosuppression

Yan Liu,Ming Chang,Zhaoliang Hu,Xin Xu,Wei Wu,Manru Ning,Taijun Hang,Min Song
DOI: https://doi.org/10.1016/j.jep.2021.113965
IF: 5.195
2021-06-01
Journal of Ethnopharmacology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Ethnopharmacological relevance</h3><p>Danggui Buxue Decoction (DBD) as a traditional Chinese medicine (TCM) has been widely used to treat blood deficiency. With the immune regulation and hematopoietic effect, DBD improved the quality of life in non-small-cell lung cancer (NSCLC) patients. We previously reported that DBD sensitized the response of NSCLC to Gemcitabine (Gem); however, the synergism and attenuation mechanism on the combination of Gem and DBD has not yet been elucidated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aim of the study</h3><p>To investigate the mechanisms of DBD in enhancing the anticancer activity of Gem and alleviating Gem-induced myelosuppression.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and methods</h3><p>A549 nude mice model was established to study the effect on the combination of Gem and DBD. The organ indices, peripheral blood cells and the hematopoiesis-related cytokines were analyzed in Gem-induced myelosuppressive mice. Then we studied the whole process from Gem-induced bone marrow suppression to self-healing, and the mechanism of DBD's attenuation by the experiments of bone marrow nucleated cells (BMNCs).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>There were an enhanced anticancer effect and an improvement of hematopoietic function by combining of Gem and DBD in A549 nude mice model. DBD regulated Hu antigen R (HuR), deoxycytidine kinase (dCK) and nuclear factor erythroid 2-related factor (Nrf2), increased the expression of thrombopoietin (TPO) and granulocyte-macrophage colony stimulating factor (GM-CSF). For Gem-induced myelosuppressive mice, DBD improved the number of peripheral blood cells and the levels of hematopoiesis-related cytokines. Moreover, DBD was observed to reduce deoxyribonucleic acid (DNA) content at the G1 phase, promoted BMNCs proliferation and up-regulated cycle-related proteins.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>The results indicated that DBD not only improved the sensitivity of Gem but also alleviated Gem-induced myelosuppression. This study may provide a pharmacological basis for the combination of DBD and Gem in clinical application.</p>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore how Danggui Buxue Decoction (DBD) can enhance the anticancer activity of gemcitabine (Gem) and relieve the side effect of myelosuppression caused by it when used in combination with gemcitabine. Specifically, the study aims to explore the synergistic mechanism of DBD combined with gemcitabine and how DBD improves gemcitabine - induced myelosuppression by analyzing the expressions of HuR, dCK and Nrf2. ### Research Background - **Gemcitabine (Gem)**: It is a commonly used chemotherapy drug for the treatment of non - small - cell lung cancer (NSCLC), but it has drug resistance and serious myelosuppression side effects. - **Danggui Buxue Decoction (DBD)**: It is a traditional Chinese medicine, which has immunomodulatory and hematopoietic functions and is often used to treat blood deficiency. ### Research Purposes - **Enhancing Anticancer Activity**: To explore whether DBD can enhance the anticancer effect of gemcitabine. - **Relieving Myelosuppression**: To study whether DBD can reduce the myelosuppression caused by gemcitabine, thereby improving the quality of life and treatment effect of patients. ### Research Methods - **Animal Models**: Use the A549 nude mouse model and the gemcitabine - induced myelosuppression mouse model. - **Experimental Design**: Divide into the control group, gemcitabine group, DBD group and gemcitabine + DBD combination group. - **Detection Indicators**: - Tumor volume and body weight changes - Peripheral blood cell count - Number of bone marrow nucleated cells (BMNCs) - Cell cycle analysis - Protein expression (Western Blot) - Gene expression (qPCR) - Histological examination (H&E staining) - Immunofluorescence detection ### Main Results - **Anticancer Effect**: The combined use of gemcitabine and DBD significantly inhibited the growth of A549 tumors, manifested as a decrease in tumor volume and more necrotic areas. - **Myelosuppression Relief**: DBD significantly increased the peripheral blood cell count and the number of bone marrow nucleated cells in gemcitabine - induced myelosuppression mice, and at the same time up - regulated the levels of hematopoietic - related cytokines (such as TPO and GM - CSF). - **Molecular Mechanisms**: DBD enhanced the anticancer effect of gemcitabine and alleviated myelosuppression by regulating the expressions of HuR, dCK and Nrf2. Specifically: - **HuR**: DBD increased the expression of HuR, especially HuR in the cytoplasm, which may promote the stability of dCK mRNA. - **dCK**: DBD up - regulated the expression of dCK, enhancing the metabolism of gemcitabine. - **Nrf2**: DBD decreased the expression of Nrf2, which may reduce the antioxidant stress response, thereby enhancing the anticancer effect of gemcitabine. ### Conclusions - **Synergistic Effect**: DBD not only enhances the anticancer effect of gemcitabine, but also significantly relieves the myelosuppression caused by gemcitabine. - **Clinical Application Potential**: This study provides a pharmacological basis for the clinical application of DBD combined with gemcitabine, and is expected to improve the treatment effect and quality of life of non - small - cell lung cancer patients. ### Formula Example - **Tumor Volume Calculation Formula**: \[ V=\frac{A\times B^{2}}{2}\] - \(V\): Tumor volume - \(A\): Tumor length - \(B\): Tumor width Through these studies, the author provides a new perspective for the combined treatment of non - small - cell lung cancer with DBD and gemcitabine, showing the potential value of traditional Chinese medicine in modern medicine.